<DOC>
	<DOCNO>NCT01723878</DOCNO>
	<brief_summary>This observational study evaluate pattern disease progression patient locally advanced metastatic non-small cell lung cancer ( NSCLC ) harbour EGFR activate mutation receive Tarceva ( erlotinib ) first-line treatment . Patients follow 12 month progression disease .</brief_summary>
	<brief_title>ASPET Study : An Observational Study Tarceva ( Erlotinib ) First Line Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating Mutations</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Histologically cytologically confirm locally advanced metastatic ( IIIB/IV ) nonsquamous nonsmall cell lung cancer ( NSCLC ) routinely evaluate clinical practice accord RECIST criterion EGFR mutationpositive disease accord local laboratory test Patients treatment Tarceva monotherapy firstline treatment accord physician 's usual practice Prior systemic therapy advance NSCLC . The administration neoadjuvant adjuvant chemotherapy allow long finalize &gt; 6 month prior receive Tarceva Participation another clinical study Patients could receive radiotherapy long irradiated lesion lesion evaluate response long radiotherapy complete initiate Tarceva treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>